Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (231-240 of 381) with videos related to

Pageof 39
Sort By:
Blood|March 25, 2009
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantationJosé L Díez-Martín, Pascual Balsalobre, Alessandro Re, et al.
Bone Marrow Transplantation|March 5, 2024
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
American Journal of Hematology|August 11, 2025
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR AnalysisJordan Gauthier, Kwang W Ahn, Jinalben Patel, et al.
Bone Marrow Transplantation|June 21, 2024
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Haematologica|July 29, 2010
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
Hemasphere|July 11, 2020
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple MyelomaAdrián Alegre, Javier de la Rubia, Anna Sureda Balari, et al.
Transplantation|October 22, 2024
Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived TherapiesNatividad Cuende, Stefan G Tullius, Ander Izeta, et al.
European Journal of Haematology|February 7, 2026
Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple MyelomaMarta Hidalgo-Soto, Luis Gerardo Rodríguez-Lobato, Cristina Motlló Borrella, et al.
The Lancet. Haematology|July 2, 2026
Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working PartyAli Bazarbachi, Ranjana Advani, Sairah Ahmed, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Pageof 39

Showing results (231-240 of 381) with videos related to

Sort By:
Pageof 39
Blood|March 25, 2009
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantationJosé L Díez-Martín, Pascual Balsalobre, Alessandro Re, et al.
Bone Marrow Transplantation|March 5, 2024
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
American Journal of Hematology|August 11, 2025
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR AnalysisJordan Gauthier, Kwang W Ahn, Jinalben Patel, et al.
Bone Marrow Transplantation|June 21, 2024
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMTAnna Sureda, Paul A Carpenter, Andrea Bacigalupo, et al.
Haematologica|July 29, 2010
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
Hemasphere|July 11, 2020
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple MyelomaAdrián Alegre, Javier de la Rubia, Anna Sureda Balari, et al.
Transplantation|October 22, 2024
Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived TherapiesNatividad Cuende, Stefan G Tullius, Ander Izeta, et al.
European Journal of Haematology|February 7, 2026
Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple MyelomaMarta Hidalgo-Soto, Luis Gerardo Rodríguez-Lobato, Cristina Motlló Borrella, et al.
The Lancet. Haematology|July 2, 2026
Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working PartyAli Bazarbachi, Ranjana Advani, Sairah Ahmed, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Pageof 39